PainChek Ltd (AU:PCK)
ASX:PCK
Want to see AU:PCK full AI Analyst Report?
Top Page
PainChek Ltd
(Sydney:PCK)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.13
▼(-56.90% Downside)
Action:Reiterated
Date:05/26/26
The score is primarily constrained by weak financial performance: despite improving revenue and gross margin, the company remains deeply loss-making with significant cash burn and negative equity. Technicals also lean bearish with the price below key longer-term moving averages and a negative MACD. Valuation is neutral-to-weak because losses make P/E less informative and there is no dividend yield data.
Positive Factors
Recurring SaaS revenue model
PainChek's subscription/usage licensing creates recurring, contract-driven revenue that scales with sites and residents. This model supports predictable cash inflows, customer stickiness and higher lifetime value versus one-off sales, forming a durable base for growth and margin improvement over months.
Negative Factors
Persistent cash burn
Operating and free cash flow near -6.8M in 2025 show sustained cash burn that erodes reserves and creates recurring funding needs. This undermines runway, increases dependency on external capital or cost cuts, and constrains investment in sales, implementation and product R&D over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring SaaS revenue model
PainChek's subscription/usage licensing creates recurring, contract-driven revenue that scales with sites and residents. This model supports predictable cash inflows, customer stickiness and higher lifetime value versus one-off sales, forming a durable base for growth and margin improvement over months.
Read all positive factors
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.26M
Dividend YieldN/A
Average Volume (3M)3.56M
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth13.69%
EPS Growth7.57%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.03
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PainChek Ltd Business Overview & Revenue Model
Company Description
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time...
How the Company Makes Money
PainChek makes money primarily by commercialising access to its PainChek software platform for healthcare and care-provider organisations. Its revenue model is typically software-based (subscription and/or usage-based licensing) where facilities o...
PainChek Ltd Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.59M | 3.36M | 2.67M | 1.95M | 978.57K | 214.80K |
| Gross Profit | 733.87K | 997.74K | 726.66K | 712.51K | -258.82K | -424.21K |
| EBITDA | -6.98M | -7.65M | -9.49M | -8.61M | -6.80M | -7.06M |
| Net Income | -6.96M | -7.67M | -8.31M | -7.57M | -5.72M | -6.06M |
Balance Sheet | ||||||
| Total Assets | 5.54M | 2.15M | 4.18M | 2.80M | 6.65M | 11.81M |
| Cash, Cash Equivalents and Short-Term Investments | 4.78M | 1.62M | 3.56M | 2.51M | 6.14M | 11.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.04M | 3.26M | 2.89M | 2.13M | 1.83M | 3.57M |
| Stockholders Equity | 2.49M | -1.11M | 1.29M | 668.13K | 4.82M | 8.24M |
Cash Flow | ||||||
| Free Cash Flow | -6.03M | -6.77M | -7.16M | -6.34M | -7.02M | -4.18M |
| Operating Cash Flow | -6.01M | -6.75M | -7.13M | -6.32M | -7.00M | -4.12M |
| Investing Cash Flow | -17.57K | -12.17K | -34.25K | -12.44K | -21.96K | -60.03K |
| Financing Cash Flow | 9.00M | 4.82M | 8.21M | 2.70M | 1.75M | 9.48M |
PainChek Ltd Technical Analysis
Negative
0.29
Price Trends
0.15
Negative
0.19
Negative
0.32
Negative
Market Momentum
>-0.01
Negative
47.32
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PCK, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.15, and below the 200-day MA of 0.32, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.32 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PCK.
PainChek Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$144.43M | 37.28 | 4.37% | ― | 36.43% | ― | |
55 Neutral | AU$19.56M | 25.20 | 7.57% | ― | 31.36% | ― | |
53 Neutral | AU$77.55M | -7.69 | -23.86% | ― | -11.45% | -97.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$27.91M | -4.83 | -14.19% | ― | 0.03% | -5.85% | |
43 Neutral | AU$29.26M | -4.09 | -1009.84% | ― | 13.69% | 7.57% |
* Healthcare Sector Average
AU:PCK
PainChek Ltd
0.14
-0.44
-75.86%
AU:M7T
Mach7 Technologies
0.33
-0.02
-5.71%
AU:RHT
Resonance Health Ltd
0.04
>-0.01
-6.82%
AU:BMT
Beamtree Holdings Ltd
0.10
-0.18
-65.71%
AU:ALC
Alcidion Group Limited
0.11
0.03
33.75%
PainChek Ltd Corporate Events
PainChek Issues Unquoted Convertible Notes to Support Capital Strategy
May 28, 2026
PainChek Ltd has notified the market of the issue of 110 unquoted convertible notes, effective 21 May 2026, under an arrangement previously outlined to investors. The securities are not quoted, and the move signals the company’s continued us...
PainChek Adds New Director With No Declared Securities Interests
May 26, 2026
PainChek Limited has appointed Lilian Bianchi as a director, effective 25 May 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Bianchi holds no relevant interests in PainChek securities a...
PainChek Plans Convertible Note and Option Issue to Bolster Capital
May 22, 2026
PainChek Ltd has notified the ASX of a proposed issue of new securities, including up to 1,100 convertible notes and 14,102,564 options exercisable at $0.30 and expiring on 25 May 2028. The securities are to be issued via a placement or similar st...
PainChek secures A$5.5m convertible note funding to accelerate U.S. expansion
May 22, 2026
PainChek Limited has raised A$5.5 million through unsecured convertible notes issued to a small group of existing professional and sophisticated shareholders, providing fresh capital to fund U.S. sales expansion and general working capital. The 12...
PainChek boosts aged care growth with major U.S. deal and rising recurring revenue
Apr 30, 2026
PainChek reported strong momentum for the March 2026 quarter, highlighted by a new master service agreement with U.S. healthcare REIT Sabra that covers 350 aged care homes and provides access to around 20,000 beds, materially enhancing its presenc...
PainChek Options Lapse Trims Potential Future Dilution
Apr 14, 2026
PainChek Ltd has announced the cessation of 1,150,000 options, designated as PCKAR, which expired unexercised on 1 March 2026. The lapse of these options slightly reduces the potential future dilution of existing shareholders but does not immediat...
PainChek strikes Sabra-funded rollout across 20,000 North American aged-care beds
Apr 13, 2026
PainChek Ltd, an Australian developer of AI-based medical devices for pain assessment, has built a global footprint spanning Australia, North America, Europe and parts of Asia, where its smartphone and tablet app supports best-practice pain manage...
PainChek Options Lapse Simplifies Capital Structure
Mar 27, 2026
PainChek Ltd has announced the expiry of 6,354,951 unexercised options with an exercise price of $0.50, which ceased on 24 March 2026. The lapse of these options, disclosed via an Appendix 3H notification, reduces the pool of potential dilutive se...
PainChek lifts UK aged care sales as global expansion gathers pace
Mar 25, 2026
PainChek has recorded strong sales momentum in the UK aged care market, securing 4,000 new contracted licences that represent 9% quarterly growth and are expected to add about A$230,000 in annual recurring revenue once rolled out. The company says...
PainChek to showcase AI pain assessment platform at virtual healthcare conference
Mar 23, 2026
PainChek Ltd, the ASX-listed developer of AI-driven pain assessment tools for healthcare, has built a globally regulated platform used in thousands of aged care facilities for more than 18 million digital pain assessments. Its smartphone and table...
PainChek Options Expire Unexercised, Simplifying Capital Structure
Mar 3, 2026
PainChek Ltd has announced the cessation of a tranche of listed options, with 16,653,867 PCKAZ options expiring unexercised on 3 March 2026. The lapse of these options slightly simplifies the company’s capital structure but does not raise ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.